Efficacy and safety of selamectin against gastrointestinal nematodes in cats presented as veterinary patients.

Author(s): Six RH, Sture GH, Thomas CA, Clemence RG, Benchaoui HA, Boy MG, Watson P, Smith DG, Jernigan AD, Rowan TG

Affiliation(s): Animal Health Clinical Affairs, Central Research Division, Pfizer Inc., Groton, CT 06340, USA. robert_h_six@groton.pfizer.com

Publication date & source: 2000-08-23, Vet Parasitol., 91(3-4):321-31.

Publication type: Clinical Trial; Multicenter Study; Randomized Controlled Trial

A series of randomized, controlled, masked, field (veterinary patient) studies were conducted in the USA and Europe to evaluate the efficacy of selamectin, a novel macrocyclic lactone of the avermectin subclass, in the treatment of naturally acquired gastrointestinal nematode infections in cats. After confirmation of ascarid and/or hookworm infection, 298 cats of various ages and breeds were randomly assigned to treatment with selamectin (n=202) or an existing commercially approved positive-control product (n=96). Unit doses of selamectin (providing a minimum dosage of 6mgkg(-1)) were administered topically to the skin in a single spot at monthly intervals. Quantitative fecal examinations were performed on days 0 (before treatment), 30, and 60. In the selamectin-treated cats, fecal ascarid egg counts were reduced by 99.6 to 100% on day 30, and by 99.9 to 100% on day 60. Fecal hookworm egg counts were reduced by 98.3% on day 30, and by 100% on day 60 in the selamectin-treated cats. The positive-control products achieved reductions in egg counts of 96.5 to 100% (ascarids) and 98.9 to 99.9% (hookworms). These studies have shown that monthly topical administration of selamectin is safe and highly effective in the treatment of naturally acquired ascarid and hookworm infections in cats.